Results 241 to 250 of about 119,989 (312)

Nanotechnology in brain cancer treatment: The role of gold nanoparticles as therapeutic enhancers

Ibrain, EarlyView.
This review highlights the potential of gold nanoparticles (AuNPs) in overcoming the blood‐brain barrier (BBB) to improve brain tumor treatment. By enabling targeted drug delivery and enhancing therapies like radiotherapy, phototherapy, and chemotherapy, AuNPs offer a promising approach for safer, more effective treatments of glioblastoma and other ...
Simona Tarantino, Annalisa Bianco, Valeria De Matteis, Edoardo Scarpa, Rosaria Rinaldi   +4 more
wiley   +1 more source

Immunotherapy in cervical cancer: an innovative approach for better treatment outcomes. [PDF]

Explor Target Antitumor Ther
Dey T, Agrawal S.
europepmc   +1 more source

Epigenomics‐guided precision oncology: Chromatin variants in prostate tumor evolution

International Journal of Cancer, EarlyView.
Abstract Prostate cancer is a common malignancy that in 5%–30% leads to treatment‐resistant and highly aggressive disease. Metastasis‐potential and treatment‐resistance is thought to rely on increased plasticity of the cancer cells—a mechanism whereby cancer cells alter their identity to adapt to changing environments or therapeutic pressures to create
Kira Furlano, Tina Keshavarzian, Nadine Biernath, Annika Fendler, Maria de Santis, Joachim Weischenfeldt, Mathieu Lupien   +6 more
wiley   +1 more source

Research status and frontiers in liver cancer immunotherapy: a bibliometric perspective on highly cited literature. [PDF]

Front Oncol
Su P, Han Y, Yi J, Hou Y, Xiao Y.
europepmc   +1 more source

TNF signature in advanced melanoma patients treated with immune checkpoint inhibitors: Results from the MELANFα clinical study

International Journal of Cancer, EarlyView.
What's New? Tumor necrosis factor (TNF) can promote tumor resistance to immune checkpoint inhibitors (ICIs), which are now the standard treatment for advanced melanoma patients. Here, in an advanced melanoma patient cohort, TNF was investigated for a possible predictive relationship with ICI response. Assessments show that after 12 weeks of ICI therapy,
Mathieu Virazels, Amélie Lusque, Stéphanie Brayer, Matthieu Genais, Carine Dufau, Jean Milhès, Thomas Filleron, Cécile Pagès, Vincent Sibaud, Laurent Mortier, Olivier Dereure, Maha Ayyoub, Amandine Fabre, Nathalie Andrieu‐Abadie, Vera Pancaldi, Céline Colacios, Nicolas Meyer, Bruno Ségui, Anne Montfort   +18 more
wiley   +1 more source

Harnessing Cellular Immunotherapy for EBV-Associated Malignancies: Current Advances and Future Directions. [PDF]

J Cell Mol Med
Gao Y, Wang D, Li C.
europepmc   +1 more source

Artificial intelligence in the diagnosis and management of gynecologic cancer

International Journal of Gynecology &Obstetrics, EarlyView.
Abstract Gynecologic cancers affect over 1.2 million women globally each year. Early diagnosis and effective treatment are essential for improving patient outcomes, yet traditional diagnostic methods often encounter limitations, particularly in low‐resource settings.
Chaiyawut Paiboonborirak, Nadeem R. Abu‐Rustum, Sarikapan Wilailak   +2 more
wiley   +1 more source

Cytokines in Focus: IL-2 and IL-15 in NK Adoptive Cell Cancer Immunotherapy. [PDF]

Immune Netw
Marr B, Jo D, Jang M, Lee SH.
europepmc   +1 more source

Plant extracellular vesicles: A promising bionic medicine platform for disease treatment and drug delivery

Interdisciplinary Medicine, EarlyView.
We introduced the basic characterization and isolation methods of PEVs, reviewed the PEVs‐related articles pertaining to disease therapy and drug delivery system, and summarized the drug loading methods, storage techniques, and engineering modification strategies of the carrier, to establish a safer, more efficient and more affordable approach for ...
Jichun Yang, Yuhan Wang, Yunqian Fu, Sitong Wang, Yao Luo, Xin Cui, Chenyu Sun, Jianing Ji, Jiaxi Mo, Yang Wang, Yilin Liu, Xinghong Hu, Xiaohui Chen, Yimin Jia, Yang Luo   +14 more
wiley   +1 more source

Research hotspots and trends in the field of immune checkpoint inhibitors (ICIs) for cervical cancer: A bibliometric study from 2014 to 2024. [PDF]

Hum Vaccin Immunother
Shen C, Zhang J, Zhang G, Luo H, Zhang S, Yuan Q, Xu W, Wang W, Miao L.   +8 more
europepmc   +1 more source